Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2901-2920 of 3,900 trials

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteInternal MedicineNeurology

Lung Cancer: Pembrolizumab Maintenance Study

We are studying whether continuing pembrolizumab treatment helps patients with stage IV lung cancer maintain disease control after initial chemotherapy. This trial will also look at the quality of life and side effects experienced by participants.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Rapamycin for Drug-Resistant Epilepsy in Children

We are studying the safety and effectiveness of rapamycin for children with drug-resistant epilepsy caused by rare central nervous system diseases. This trial aims to find better treatment options for these challenging conditions.

Epilepsy and Related Disorders>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

High-Grade Glioma in Children: Rapamycin Study

We are evaluating the safety and effectiveness of rapamycin for treating high-grade gliomas in children. This study aims to understand how well it works and if genetic factors play a role in treatment response.

High Grade Glioma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

DIPG Treatment: Targeted Drug Study for Children

We are testing how well certain drugs work for children with diffuse intrinsic pontine glioma (DIPG) based on their tumor's genetic makeup. The goal is to find safer and more effective treatments tailored to individual patients.

Diffuse Intrinsic Pontine Glioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Myelofibrosis: Study of Pacritinib vs. Standard Treatment

We are investigating whether pacritinib can better reduce spleen size and improve symptoms in patients with myelofibrosis. This trial is for those with severe low platelet counts and compares pacritinib to physician's choice of therapy.

Post-Polycythaemia Vera MyelofibrosisPrimary MyelofibrosisPost-Essential Thrombocythaemia Myelofibrosis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Acute Cholecystitis: Antibiotic Treatment Comparison

We are studying whether a single dose of antibiotics before gallbladder surgery is as effective as continuous antibiotics in preventing infections. This trial aims to improve patient outcomes during and after surgery.

Acute Cholecystitis>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Hidradenitis Suppurativa: Brensocatib Study

We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.

Hidradenitis Suppurativa1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Brain Health: 5-HT2A Receptor Study

We are investigating how changes in the 5-HT2A receptor may impact brain function. This research could help us understand treatments for various neurological conditions.

Healthy ParticipantsSafety phase (I)NeurologyPsychiatry

Dystonia: Botulinum Toxin for Arm Tremors

We are exploring how different tests and imaging techniques can help determine the effectiveness of botulinum toxin for treating arm tremors in people with dystonia. This study aims to improve treatment options for those affected.

Dystonic Tremor Syndrome6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Generalized Myasthenia Gravis: IMVT-1402 Study

We are testing a new treatment for people with mild to severe generalized myasthenia gravis. The study aims to see if it can improve muscle strength and reduce symptoms.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)Investigational MedicinesCost ReimbursementNeurology

Oligometastatic Peritoneal Gastric Cancer: PIPAC Treatment Study

We are studying whether adding pressurized intraperitoneal aerosol chemotherapy (PIPAC) to standard chemotherapy helps patients with oligometastatic peritoneal gastric cancer have better surgery outcomes and longer survival.

Metastatic Gastric Adenocarcinoma1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology

Lung Cancer Treatment: Chemotherapy + Atezolizumab

We are studying a combination of chemotherapy and atezolizumab for patients with stage IIIA and IIIB non-small cell lung cancer. This trial aims to see if this approach improves survival and treatment outcomes before and after surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Cardiac Arrest: Ketamine vs. Propofol Sedation

We are studying whether ketamine sedation can better protect the brain and improve survival compared to propofol in patients resuscitated from cardiac arrest. This trial looks at outcomes at discharge and 180 days later.

Out-of-Hospital Cardiac Arrest1-2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Nevoid Basal Cell Carcinoma Syndrome: Sonidegib Treatment Study

We are studying the effects of Sonidegib on patients with Nevoid Basal Cell Carcinoma Syndrome and sporadic basal cell carcinoma. The trial will assess treatment effectiveness, safety, and quality of life improvements.

Nevoid Basal Cell Carcinoma Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Out-of-Hospital Cardiac Arrest: DANOHCA Study

We are testing different treatments, including medications and positioning, for patients who have had a cardiac arrest outside the hospital. Our goal is to see which methods may improve survival and recovery.

Cardiac Arrest>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInternal Medicine

Cardiac Surgery: Dexamethasone and Olanzapine Study

We are investigating whether dexamethasone and olanzapine improve recovery for adults undergoing heart surgery. The study also looks at different management techniques to enhance patient outcomes after surgery.

Ischemic Heart DiseaseHeart Valve Surgery>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInternal Medicine

Post-Surgical Hypoparathyroidism: Indapamide Treatment

We are studying whether daily Indapamide can help manage calcium levels in patients with post-surgical hypoparathyroidism. This trial will also look at the safety of the treatment and its effects on urinary calcium excretion.

Hypoparathyroidism≤3 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyInternal Medicine

Crohn's Disease: Adalimumab Treatment Study

We are comparing a new approach using adalimumab for newly diagnosed Crohn's disease patients against standard treatments. The goal is to see which method is safer and more effective in the long run.

Crohn's Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine